1. Home
  2. GKOS

as 07-04-2025 12:33pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medical/Dental Instruments

Nasdaq

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Founded: 1998 Country:
United States
United States
Employees: N/A City: ALISO VIEJO
Market Cap: 5.8B IPO Year: 2015
Target Price: $135.15 AVG Volume (30 days): 903.0K
Analyst Decision: Strong Buy Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.27 EPS Growth: N/A
52 Week Low/High: $77.10 - $163.71 Next Earning Date: 07-30-2025
Revenue: $404,523,000 Revenue Growth: 23.92%
Revenue Growth (this year): 27.88% Revenue Growth (next year): 27.60%

GKOS Daily Stock ML Predictions

Share on Social Networks: